HUTCHMED(HCM) - 2021 Q4 - Annual Report

Exhibit 99.1 HUTCHMED Reports 2021 Full Year Results and Provides Business Updates Oncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE growth and the 2021 launches of SULANDA and ORPATHYS; Positive SAVANNAH, CALYPSO and VIKTORY studies triggered five registration studies on ORPATHYS in lung cancer, kidney and gastric cancer during 2021; Broad late-stage development program – currently enrolling 13 registration studies on 6 assets – with enrollment on the 691 patient FRESCO-2 global Phase ...